Russia to veto UN SC resolution on tribunal over MH17 crash if it scores 9 votes — envoy
Putin and Erdogan did not discuss Turkish Stream during Sunday’s phone talks — Kremlin
Russia not planning to deploy Tu-22M3 bomber in Crimea
Russian fifth-generation PAK FA fighter to take part in MAKS-2015 airshow in Moscow
Deserted burial site found in east Ukraine by DPR militia
Putin says no anti-Americanism in Russia, calls for Europe’s independenceRussia July 28, 2:01
Russia not seeking confrontation but will defend its interests - PutinRussia July 27, 23:40
Putin may attend UN General Assembly session in September, no decision as of yet — KremlinRussia July 27, 21:47
Minister: Russian football 's return to spring-autumn format possible only after World CupSports July 27, 21:36
Russia to cooperate with Kazakhstan within WTO — ministryEconomy July 27, 21:16
Lawmaker Valeriu Strelet nominated as candidate for Moldova’s prime ministerWorld July 27, 20:45
Russia’s Kaluga to host production of Yota smartphones for law enforcement agenciesEconomy July 27, 20:38
WTO director-general hopes Kazakhstan joins trade body by DecemberEconomy July 27, 20:15
Armenia energy protests: Sit-in launched in Yerevan’s central squareWorld July 27, 20:09
KHIMKI, September 6. (ITAR-TASS) – Russian scientists are currently working on the first ever vaccine which could help quit smoking; it may be available in pharmacies in as early as five years. Dmitry Ovchinnikov, Deputy Director General of the company developing the drug, Selecta RUS confirmed: “We’re currently going through the second phase of clinical trials.”
Selecta RUS is a subsidiary of an American innovation company which opened the Khimki branch in 2012. Ovchinnikov said that development of the ‘anti-tobacco’ and other vaccines was moved from the U.S. to Russia, as “experts of required qualification work here.” Favorable financing conditions were also a factor: for instance, the vaccine project has received a grant from Russia’s Ministry of Industry and Trade.
The scientists noted that “existing methods of curing tobacco addiction are ineffective,” adding that the new vaccine will be a breakthrough. The drug makes recipient’s body start producing antibodies which block nicotine before it reaches the brain.
Khimki lab scientists are working on a molecular “nano-container,” which can precisely deliver vaccine components in cells which are responsible for launching immune reaction. Produced anti-bodies bind nicotine contained in blood; the resulting complex becomes too large to bypass the blood–brain barrier, which restrict diffusion of dangerous microscopic objects, such as bacteria and harmful molecules. As a result, nicotine cannot access the brain’s “pleasure center” – thus smoking ceases to bring the feeling of euphoria and satisfaction. The chain of pathological tobacco addiction is thus broken.
Ovchinnikov added that Selecta RUS scientists are also working on other vaccines against other afflictions such as melanoma, type 1 diabetes and hepatitis B.
“Operation of this laboratory is a vivid example of technology transfer to Russia,” said Sergei Filippov, representative of Rusnano. He added that Rusnano owns 12% of SelectaBiosciences, the American company which owns Selecta RUS.